Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia:: is this the real target?

被引：12

作者：

Malagola, M ^{[1
]}

Martinelli, G ^{[1
]}

Rondoni, M ^{[1
]}

Paolini, S ^{[1
]}

Gaitani, S ^{[1
]}

Arpinati, M ^{[1
]}

Piccaluga, PP ^{[1
]}

Amabile, M ^{[1
]}

Basi, C ^{[1
]}

Ottaviani, E ^{[1
]}

Candoni, A ^{[1
]}

Gottardi, E ^{[1
]}

Cilloni, D ^{[1
]}

Bocchia, M ^{[1
]}

Saglio, G ^{[1
]}

Lauria, F ^{[1
]}

Fanin, R ^{[1
]}

Visani, G ^{[1
]}

Marré, MC ^{[1
]}

Maderna, M ^{[1
]}

Rancati, F ^{[1
]}

Vinaccia, V ^{[1
]}

Russo, D ^{[1
]}

Baccarani, M ^{[1
]}

机构：

[1] Policlin S Orsola, Inst Hematol & Med Oncol L & A Seragnoli, I-40138 Bologna, Italy

来源：

BLOOD | 2005年 / 105卷 / 02期

关键词：

D O I：

10.1182/blood-2004-08-3088

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：904 / 904

页数：1

共 50 条

[1] Imatinib in patients with c-kit-positive acute myeloid leukemia
Kindler, T
Heidel, R
Fischer, T
BLOOD, 2005, 105 (02) : 905 - 905
[2] Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia
Kindler, T
Breitenbuecher, F
Marx, A
Beck, J
Hess, G
Weinkauf, B
Duyster, J
Peschel, C
Kirkpatrick, CJ
Theobald, M
Gschaidmeier, H
Huber, C
Fischer, T
BLOOD, 2004, 103 (10) : 3644 - 3654
[3] A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia
Advani, Anjali S.
Tse, William
Li, Hong
Jia, Xuefei
Elson, Paul
Cooper, Brenda
Ali-Osman, Francis
Park, Jino
Rao, Arati, V
Rizzieri, David A.
Wang, Eunice S.
Cotta, Claudiu, V
Kalaycio, Matt
Sobecks, Ronald M.
Rouphail, Basel
Maciejewski, Jaroslaw P.
Fensterl, Jaime
Carew, Jennifer S.
Foster, Bethany
Rush, Mary Lynn
Tripp, Barbara
Adams, Donna
Corrigan, Donna
Griffiths, Elizabeth A.
Sekeres, Mikkael A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02): : 113 - 118
[4] Imatinib mesylate as second-line treatment in a c-kit-positive esthesioneuroblastoma
Kim, S.
Atta, J. R.
Bergmann, L.
Ottmann, O. G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5] A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
Advani, Anjali S.
Tiu, Ramon
Saunthararajah, Yogen
Maciejewski, Jaroslaw
Copelan, Edward A.
Sobecks, Ronald
Sekeres, Mikkael A.
Bates, Jennifer
Rush, Mary Lynn
Tripp, Barbara
Salvado, August
Noon, Elysa
Howard, Matthew
Jin, Tao
Hsi, Eric
Egorin, Merrill J.
Lim, Kathleen
Cotta, Claudiu V.
Price, Courtney
Kalaycio, Matt
LEUKEMIA RESEARCH, 2010, 34 (12) : 1622 - 1626
[6] C-kit-positive acute myelogenous leukemia effectively treated with imatinib: A case report and review of the literature
Ichikawa, Kunimoto
Aritaka, Nanae
Sekiguchi, Yasunobu
Sugimoto, Kei-ji
Imai, Hidenori
Komatsu, Norio
Noguchi, Masaaki
GERIATRICS & GERONTOLOGY INTERNATIONAL, 2012, 12 (04) : 762 - 764
[7] Treatment of chronic myeloid leukemia with imatinib mesylate
Ohno R.
International Journal of Clinical Oncology, 2006, 11 (3) : 176 - 183
[8] Imatinib mesylate and treatment of chronic myeloid leukemia
Yamada, Hisashi
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 39P - 39P
[9] Imatinib mesylate for the treatment of chronic myeloid leukemia
Soverini, Simona
Martinelli, Giovanni
Lacobucci, Ilaria
Baccarani, Michele
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (06) : 853 - 864
[10] A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML)
Advani, Anjali
Cooper, Brenda
Sowunmi, Olumuyiwa
Elson, Paul
Ali-Osman, Francis
Park, Jino
Rao, Arati
Rizzieri, David A.
Wang, Eunice S.
Cotta, Claudiu
Sekeres, Mikkael A.
Kalaycio, Matt
Sobecks, Ronald
Rouphail, Basel
Maciejewski, Jaroslaw P.
Davis, Randall
Bailey, Laura
Foster, Bethany
Rush, Mary Lynn
Adams, Donna
Tse, William
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →